Novo Nordisk A/S (NVO) to Issue Dividend of $0.58 on August 25th

Posted by Andrew Walz on Aug 7th, 2026

Novo Nordisk A/S (NYSE:NVO – Get Free Report) declared a dividend on Wednesday, August 5th. Shareholders of record on Monday, August 17th will be paid a dividend of 0.5786 per share on Tuesday, August 25th. This represents a yield of 254.0%. The ex-dividend date of this dividend is Monday, August 17th.

Novo Nordisk A/S has raised its dividend by an average of 0.2%per year over the last three years. Novo Nordisk A/S has a payout ratio of 36.9% meaning its dividend is sufficiently covered by earnings. Research analysts expect Novo Nordisk A/S to earn $3.28 per share next year, which means the company should continue to be able to cover its $1.74 annual dividend with an expected future payout ratio of 53.0%.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $45.90 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The company’s fifty day moving average price is $46.96 and its two-hundred day moving average price is $45.01. The firm has a market capitalization of $204.96 billion, a P/E ratio of 11.22, a P/E/G ratio of 4.06 and a beta of 0.76. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $64.16.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last announced its earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%.The company had revenue of $11.98 billion during the quarter. On average, research analysts anticipate that Novo Nordisk A/S will post 3.39 earnings per share for the current fiscal year.

About Novo Nordisk A/S

(Get Free Report)

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.